

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – BUSINESS UPDATE ON THE IN-LICENSING AND RESEARCH AND DEVELOPMENT OF TAFOXIPARIN OF THE GROUP

This announcement is made by the board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**” or “**Lee’s Pharm**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

Reference is made to the license agreement entered into between the Company and Dilafor AB (“**Dilafor**”), a Swedish drug development company focusing on the development of Tafoxiparin for obstetric indications, in February 2014 to manufacture, develop and commercialise Tafoxiparin for obstetrical and gynecological indications in China, Hong Kong, Macau and Taiwan.

The Board of the Company is pleased to announce that on 22 October 2021, Dilafor has enrolled the first patient in a clinical Phase 2a study with Tafoxiparin in pregnant women diagnosed with preeclampsia. This exploratory, open label, randomised, parallel-group, Phase 2a pilot study will evaluate the safety, tolerability, and efficacy of daily subcutaneous Tafoxiparin treatment from the time of diagnosis for up to 4 weeks. The study is planned to include 23 pregnant women in 26 to 34 weeks of gestation who are diagnosed with preeclampsia. The pregnant women will be randomised to either subcutaneous injection of Tafoxiparin and standard of care or only standard of care, which is usually symptomatic treatment with anti-hypertensive drugs.

Preeclampsia is diagnosed in 5–8% of all pregnant women globally and can lead to severe fetal and maternal complications. One third of cases are severe in degree with extreme risk of preterm birth and maternal and fetal sequela. Long-term vascular complications, including stroke and cardiovascular problems, are reported early in life in women with a history of preeclampsia. The condition consistently remains among the top three causes of maternal death in both high-income and low-income countries.

* *For identification purpose only*

ABOUT TAFOXIPARIN

Tafoxiparin is a proprietary polysaccharide based drug developed by Dilafor. Women that experience protracted and complicated labor have deficiency in a naturally occurring submucosal molecule that plays an important role in labor. Preclinical and clinical data show that Tafoxiparin fulfills the role of this molecule and works in conjunction with naturally occurring molecules important in childbirth.

ABOUT DILAFOR

Dilafor AB is a Swedish drug development company focusing on the development of Tafoxiparin for obstetric indications. The company's primary goal is to decrease the incidence of slow progress of labor both after induction of labor and after spontaneous onset of labor. More information at www.dilafor.com.

ABOUT LEE'S PHARM

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with over 20 international companies and currently markets 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology and obstetrics, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies. More information at www.leespharm.com.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 27 October 2021

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive directors of the Company, Dr. Li Xiaoyi is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.